Scientists from the Terasaki Institute for Biomedical Innovation have developed a nanoengineered bioink with improved bonding and cross-linking capabilities for 3D bioprinting of tumor models.
Medtronic focused on delivering durable revenue and profit growth
Listen to the article 5 min This audio is auto-generated. Please let us know if you have feedback. Medtronic CEO Geoff Martha said new product